Harnessing Cross-Talk Between Signaling Pathways to Improve Cancer Treatment
Michael B. Yaffe, Koch Institute at MIT watch...
The David H. Koch Institute for Integrative Cancer Research at MIT
Science + Engineering... Conquering Cancer Together
Michael B. Yaffe, Koch Institute at MIT watch...
September 20, 2012
Systems Bio
Michael Yaffe, Koch Institute watch...
KI member Michael Yaffe and his laboratory team report finding, in the May 11 issue of Cell, that staggering the doses of two common cancer drugs dramatically boosts their ability to kill a particularly malignant type of breast cancer cells. Yaffe has been studying the complex cell signaling pathways of cancer cells and the ability of dysfunctional pathways to promote uncontrolled cell growth. He is now working with researchers at Dana Farber Cancer Institute to plan clinical trials of the novel approach. more...
A conversation with Michael B. Yaffe about research articles published in Science Signaling in 2009. more...
Michael B. Yaffe, Professor of Biology and Biological Engineering watch...
New work by MIT cancer biologists shows that the interplay between two key genes that are often defective in tumors determines how cancer cells respond to chemotherapy. The findings should have an immediate impact on cancer treatment, say Michael Hemann and Michael Yaffe, the two MIT biology professors who led the study. The work could help doctors predict what types of chemotherapy will be effective in a particular tumor, which would help tailor treatments to each patient. more...
In Cell, KI researcher describe how computer simulations can reveal the inner workings and vulnerabilities of a cancer. The results reveal new ways in which cells process chemical information and could indicate how to maximize the effectiveness of disease treatments such as chemotherapy. more...
